New Spanish Clinical Data from Proclarix® with Magnetic Resonance Imaging for Improved Prostate Cancer Diagnosis Will Be Presented at the 36th Annual European Urology Congress
Poster Session 35: Prostate cancer screening, biopsy indication protocols and markers – Monday, July 12, 2021, 11:30 AM-12:30 PM.
Abstract P1011 – Retrospective evaluation of Proclarix as a companion to mpMRI for the detection of clinically significant prostate cancer.
Abstract P1017 – Retrospective evaluation of Proclarix for the detection of clinically significant prostate cancer together with mpMRI
Presenter: M. Campistol Torres, Universitat Autònoma de Barcelona, Vall d’Hebron University Hospital, Barcelona, Spain.
The two posters highlight the fact that Proclarix® can be used with high confidence in routine practice. The risk of missing clinically significant cancer was 5% or lower. With an NPV of 94%, Proclarix reliably rules out patients with no or insignificant cancer. Performance of Proclarix was better than %fPSA, PSA density, and risk calculators with, at equal sensitivity, higher specificity, PPV, and higher reduction of unneeded biopsies with a clinically relevant saving of one out of three unneeded biopsies. In addition, it was demonstrated that Proclarix can even be safely used in men with an extended range of elevated PSA up to 20 ng/ml, disregard of DRE status or prostate volume.
When Proclarix was combined with MRI into a single score, no or indolent cancers were ruled out with significantly better performance than PSA density or PI-RADS score alone and significantly higher reduction of up to 3 out of 4 unneeded biopsies was achieved.
Source: "News/Resources". 2021. Proteomedix.Com.